Literature DB >> 20980526

An in-depth analysis of original antigenic sin in dengue virus infection.

Claire M Midgley1, Martha Bajwa-Joseph, Sirijitt Vasanawathana, Wannee Limpitikul, Bridget Wills, Aleksandra Flanagan, Emily Waiyaiya, Hai Bac Tran, Alison E Cowper, Pojchong Chotiyarnwong, Pojchong Chotiyarnwon, Jonathan M Grimes, Sutee Yoksan, Prida Malasit, Cameron P Simmons, Juthathip Mongkolsapaya, Gavin R Screaton.   

Abstract

The evolution of dengue viruses has resulted in four antigenically similar yet distinct serotypes. Infection with one serotype likely elicits lifelong immunity to that serotype, but generally not against the other three. Secondary or sequential infections are common, as multiple viral serotypes frequently cocirculate. Dengue infection, although frequently mild, can lead to dengue hemorrhagic fever (DHF) which can be life threatening. DHF is more common in secondary dengue infections, implying a role for the adaptive immune response in the disease. There is currently much effort toward the design and implementation of a dengue vaccine but these efforts are made more difficult by the challenge of inducing durable neutralizing immunity to all four viruses. Domain 3 of the dengue virus envelope protein (ED3) has been suggested as one such candidate because it contains neutralizing epitopes and it was originally thought that relatively few cross-reactive antibodies are directed to this domain. In this study, we performed a detailed analysis of the anti-ED3 response in a cohort of patients suffering either primary or secondary dengue infections. The results show dramatic evidence of original antigenic sin in secondary infections both in terms of binding and enhancement activity. This has important implications for dengue vaccine design because heterologous boosting is likely to maintain the immunological footprint of the first vaccination. On the basis of these findings, we propose a simple in vitro enzyme-linked immunosorbent assay (ELISA) to diagnose the original dengue infection in secondary dengue cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20980526      PMCID: PMC3014204          DOI: 10.1128/JVI.01826-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

Authors:  M Simmons; G S Murphy; C G Hayes
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

2.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

Authors:  Richard J Kuhn; Wei Zhang; Michael G Rossmann; Sergei V Pletnev; Jeroen Corver; Edith Lenches; Christopher T Jones; Suchetana Mukhopadhyay; Paul R Chipman; Ellen G Strauss; Timothy S Baker; James H Strauss
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

3.  Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice.

Authors:  Eiji Konishi; Saori Kosugi; Jun-ichi Imoto
Journal:  Vaccine       Date:  2005-11-15       Impact factor: 3.641

Review 4.  Prospects for a dengue virus vaccine.

Authors:  Stephen S Whitehead; Joseph E Blaney; Anna P Durbin; Brian R Murphy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 5.  Progress towards a dengue vaccine.

Authors:  Daniel P Webster; Jeremy Farrar; Sarah Rowland-Jones
Journal:  Lancet Infect Dis       Date:  2009-11       Impact factor: 25.071

6.  Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin".

Authors:  D C Powers; R B Belshe
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

7.  Antibody-enhanced dengue virus infection in primate leukocytes.

Authors:  S B Halstead; E J O'Rourke
Journal:  Nature       Date:  1977-02-24       Impact factor: 49.962

8.  Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination.

Authors:  Upma Gulati; Kshama Kumari; Wenxin Wu; Wendy A Keitel; Gillian M Air
Journal:  Vaccine       Date:  2005-02-03       Impact factor: 3.641

9.  Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism.

Authors:  Philippe Thullier; Caroline Demangel; Hugues Bedouelle; Françoise Mégret; Alain Jouan; Vincent Deubel; Jean-Claude Mazié; Pierre Lafaye
Journal:  J Gen Virol       Date:  2001-08       Impact factor: 3.891

10.  Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection.

Authors:  B M Kaufman; P L Summers; D R Dubois; K H Eckels
Journal:  Am J Trop Med Hyg       Date:  1987-03       Impact factor: 2.345

View more
  92 in total

1.  B-cell responses during primary and secondary dengue virus infections in humans.

Authors:  Anuja Mathew; Kim West; Siripen Kalayanarooj; Robert V Gibbons; Anon Srikiatkhachorn; Sharone Green; Daniel Libraty; Smita Jaiswal; Alan L Rothman
Journal:  J Infect Dis       Date:  2011-09-19       Impact factor: 5.226

2.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

3.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

Review 4.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

5.  Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity.

Authors:  Poornima Parameswaran; Patrick Charlebois; Yolanda Tellez; Andrea Nunez; Elizabeth M Ryan; Christine M Malboeuf; Joshua Z Levin; Niall J Lennon; Angel Balmaseda; Eva Harris; Matthew R Henn
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

6.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

7.  Antibody-based assay discriminates Zika virus infection from other flaviviruses.

Authors:  Angel Balmaseda; Karin Stettler; Raquel Medialdea-Carrera; Damaris Collado; Xia Jin; José Victor Zambrana; Stefano Jaconi; Elisabetta Cameroni; Saira Saborio; Francesca Rovida; Elena Percivalle; Samreen Ijaz; Steve Dicks; Ines Ushiro-Lumb; Luisa Barzon; Patricia Siqueira; David W G Brown; Fausto Baldanti; Richard Tedder; Maria Zambon; A M Bispo de Filippis; Eva Harris; Davide Corti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

Review 8.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

9.  Sequential immunization induces strong and broad immunity against all four dengue virus serotypes.

Authors:  Jue Hou; Shubham Shrivastava; Hooi Linn Loo; Lan Hiong Wong; Eng Eong Ooi; Jianzhu Chen
Journal:  NPJ Vaccines       Date:  2020-07-24       Impact factor: 7.344

10.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.